Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Study of Keynatinib in Patients With Advanced Non-small Cell Lung Cancer With Brain Metastasis or Progression of Brain Metastasis After Treatment With EGFR Inhibitor(s)

NCT04824079 is registered in ClinicalTrials.gov with Medolution Ltd. as lead sponsor.

NCT NCT04824079
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04824079 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Study of Keynatinib in Patients With Advanced Non-small Cell Lung Cancer With Brain Metastasis or Progression of Brain Metastasis After Treatment With EGFR Inhibitor(s)
Lead sponsor
Medolution Ltd.
Phase
Phase 2
Overall status
Completed
Start date
October 21, 2020
Completion date
December 10, 2024
Enrollment
16 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

brain metastases, non-small cell lung cancer with egfr mutation